Fig. 4
From: Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease
AS-IV suppresses MPP+ /LPS-induced senescence of astrocytes. Astrocytes were pretreated with AS-IV (50 μM) for 1 h before MPP+ (200 μM) or LPS (500 ng/ml) stimulation for 24 h. a, b Representative immunoblots (a) and quantitative analysis of p16Ink4a (b) in astrocytes treated with AS-IV and MPP+. Quantified data are normalized to the control group (the control group value is equal to 1). c–i qPCR of p16INK4a (c), IL-6 (d), IL-1β (e), IL-1α (f), CXCL1 (g), MMP3 (h), and MMP9 (i) mRNA levels. j, k Representative immunoblots (j) and quantitative analysis of p16Ink4a (k) in astrocytes treated with AS-IV and LPS. Quantified data are normalized to the control group (the control group value is equal to 1). l–n qPCR of p16INK4a (l), MMP3 (m), and CXCL1 (n) mRNA levels. The data shown are the mean ± SEM from three independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. AS-IV, Astragaloside IV; MPP+, 1-methyl-4-phenylpyridinium; LPS, lipopolysaccharide